Navigation Links
Amgen's Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94
Date:10/22/2013

t demand.
  • Combined sales of Vectibix and Nplate® (romiplostim) increased 19 percent year-over-year mainly due to unit growth.
  • XGEVA sales increased 30 percent year-over-year and 5 percent on a sequential basis, reflecting increased segment share.
  • Prolia sales increased 62 percent year-over-year due to increased segment share and decreased 5 percent on a sequential basis impacted by seasonality.
  • Product Sales Detail by Product and Geographic Region$Millions, except percentagesQ3 '13Q3 '12YOY ΔUSROWTOTALTOTALTOTALNeulasta®/ NEUPOGEN®$1,314

    $287

    $1,601$1,35518%Neulasta®905

    230

    1,1351,0449%NEUPOGEN®409

    57

    46631150%Enbrel®1,073

    82

    1,1551,0797%Aranesp®171

    278

    449497(10%)EPOGEN®491

    0

    4914910%Sensipar® / Mimpara®183

    76

    2592437%Vectibix®32

    75

    1078822%Nplate®58

    48

    1069116%XGEVA®/ Prolia®303

    136

    43931141%XGEVA®194

    67

    26120130%Prolia®109

    69

    17811062%Other 0

    40

    4046(13%)Total product sales$3,625

    $1,022

    $4,647$4,20111%Operating Expense and Tax Rate Analysis, on an Adjusted Basis

  • Cost of Sales margin decreased 0.6 points.
  • R&D expenses increased 14 percent in the third quarter of 2013 primarily in support of our later-stage clinical programs, particularly evolocumab (AMG 145) and the $50 million upfront payment to Servier for the U.S. rights to ivabradine.
  • Selling, General & Administrative (SG&A) expenses increased 10 percent driven primarily by higher ENBREL profit share expenses and the U.S. h
    '/>"/>

  • SOURCE Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
    2. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
    3. Pro-Dex, Inc. Announces Fiscal 2012 Third Quarter Financial Results Conference Call and Webcast
    4. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
    5. Cardica Announces Fiscal 2012 Third Quarter Financial Results
    6. Hill-Rom Announces Third Quarter 2012 Dividend
    7. Cardinal Health Reports Third-Quarter Results
    8. TPI to Host Third Quarter of Fiscal Year 2012 Earnings Conference Call on Tuesday, May 15, 2012 at 9:00 a.m. ET
    9. Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results
    10. ThermoGenesis Corp. To Announce Third Quarter Fiscal 2012 Results On May 10, 2012
    11. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/5/2015)... , Mar. 05, 2015 Research and Markets ... of the "Japan Pharma Outlook 2015: Year to ... Strategic Initiatives" report to their offering. ... Japan from April -2014 (Annexure 1) is ... companies - whether generic or innovator. The most of ...
    (Date:3/5/2015)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... be held March 8-11, 2015, in Laguna ... , Chief Executive Officer, will provide an overview of ... be available to participate in one-on-one meetings with investors ...
    (Date:3/5/2015)... 5, 2015 According to a ... Product (Systems and Disposables), by Type (Invasive, Minimally Invasive, ... and Ambulatory Sites) - Analysis & Global Forecast to ... expected to reach $1,107.4 Million by 2019 from $887.8 ... a CAGR of 4.5% during the forecast period. ...
    Breaking Medicine Technology:Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 2Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 3ContraVir to Present at 27th Annual ROTH Conference 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 3Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 4
    ... 24, 2007 - Bentley,Pharmaceuticals, Inc. (NYSE: BNT), ... late breaking abstract sponsored by,the Company has ... the,American Diabetes Association 67th Scientific Sessions in ... Single-Dose,2/3-Way Crossover Comparison Study of Intranasal Insulin ...
    ... 23 May 2007 - The antidepressant duloxetine,hydrochloride was ... who did not respond, or responded only,partially, to ... of whether those patients were,switched from an SSRI ... presented today at the American Psychiatric,Association’s 160 th ...
    Cached Medicine Technology:Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 2Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 3In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 2In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 3In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 4In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 5In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 6In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 7In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 8In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 9
    (Date:3/5/2015)... 05, 2015 This week, ... in low-cost laminate flooring products, initiating widespread concern ... eco-friendly building materials made primarily from bamboo, stands ... all their flooring products for volatile organic compounds ... Benchmark International (BMH). Results from formaldehyde emissions ...
    (Date:3/5/2015)... 05, 2015 Risperdal lawsuits ( ... Pennsylvania mass tort litigation currently underway in the ... has begun hearing testimony in the proceeding’s second ... medication can cause gynecomastia, or male breast growth. ... was filed on behalf of a plaintiff who ...
    (Date:3/5/2015)... Rhode Island Medical Imaging (RIMI) was pleased ... to support the Providence College (PC) women’s basketball program’s fight ... of the ‘Think Pink’ uniforms, which were worn during the ... DePaul University at Alumni Hall/Mullaney Gymnasium in Providence, R.I. ... the PC women’s basketball’s ‘Pink Out’ event,” said Dr. Scott ...
    (Date:3/5/2015)... Los Angeles, CA (PRWEB) March 05, 2015 ... online article titled “Butt Augmentation, Labiaplasty on the Rise, ... surveys reported by the American Society for Aesthetic ... Plastic Surgeons . Both groups reported a year-over-year doubling ... one of the physicians quoted in the article, this ...
    (Date:3/5/2015)... 2015 TCS Healthcare Technologies (TCS), a ... population health management arena, is pleased to announce a ... ACUITY Advanced Care™ (ACUITY) version 7.20. The session will ... the advantages of automation. , The webinar, scheduled for ... led by Jeff Frater, RN, BSN, Director of Partner ...
    Breaking Medicine News(10 mins):Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 3
    ... research reports published in the new issue of Archives ... vascular birthmarks with treatment procedures like laser therapy and ... internal, or form an external birthmark and can be ... ,The researchers had presented the current treatment approaches for ...
    ... genetic disorder characterized by distorted, sickle shaped red blood cells. ... damage to the kidneys, spleen, and liver. The sickle cell ... is about 1 in 500., ,Despite much clinical work, ... can be relieved, and the frequency and duration of the ...
    ... Researchers at the University of California in San Francisco ... fruit and vegetables can reduce the risk of pancreatic ... most strongly associated with increased // protection were onions, ... potatoes, corn and yellow squash), dark leafy vegetables and ...
    ... medical journal The Lancet had published a research ... health workers., ,Poor health-worker performance is a ... In the current issue of The Lancet researchers ... for how high-quality health-worker performance can be achieved., ...
    ... Molecular Immunologist and his team has found a new virus ... inflammation and autoimmune diseases. The new delivery system acts as ... virus containing the required genes are transferred into the T ... the immune cells they get attracted towards the cancer cell ...
    ... have been reported to experience 25% less muscle and joint ... active. Furthermore, the study has also revealed that people who ... experience less pain than non-runners even though they are more ... study involved comparison of the level of pain in a ...
    Cached Medicine News:Health News:Hydroxyurea Treatment For Children With Sickle Cell Disease 2
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: